Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2516 pharmacodynamics in healthy males
NCT01154634Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2010
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of AZD2516 in gastroesophageal reflux disease (GERD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Reflux Episodes 0 to 3 Hours Post Meal. Started May 2010; status: completed.
02
Drugs
AZD2516
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01154634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154634.